Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
DiabetesontheNet Logo
×
This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed Communications has provided editorial, marketing and logistical support.

Click here to view Great Britain and Northern Ireland prescribing information

Management of adults with type 2 diabetes and chronic kidney disease:

What do recent guideline updates say about the role of SGLT2 inhibitors?

ABOUT THE WEBINAR

Chronic kidney disease (CKD) is a potentially devastating condition in adults with type 2 diabetes.1 However, timely diagnosis through regular screening and early treatment may slow the progression of the condition.2

NICE has recently recommended use of certain sodium-glucose co-transporter 2 (SGLT2) inhibitors in addition to an angiotensin receptor blocker or an angiotensin-converting enzyme inhibitor at an optimised dose in adults with type 2 diabetes and CKD whose albumin:creatinine ratio is more than 30 mg/mmol. Meanwhile, the UK Kidney Association recently published guidelines recommending the use of SGLT2 inhibitors in adults with type 2 diabetes and an ACR ≥25 mg/mmol, and suggesting their use in suitable patients with an ACR >3 mg/mmol.4

This live webcast on 15 December 2021 at 13.00 and 19.00 will discuss key points from the recently published NICE recommendations for the management of adults with type 2 diabetes and CKD. The importance of early screening for CKD in adults with type 2 diabetes and the potential impact these updates will have on clinical practice and the prescribing of SGLT2 inhibitors will also be explored.

 

References

  1. KDIGO Diabetes Work Group. Kidney Int 2020;98:S1–115
  2. Winocour PH et al. Diabetes & Primary Care 2020;22: 99–109
  3. NICE (2021) Chronic kidney disease: assessment and management (NG203). Available at: https://www.nice.org.uk/guidance/ng203 (accessed October 2021)
  4. UK Kidney Association (2021). Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. Available at: https://ukkidney.org/health-professionals/guidelines/guidelines-commentaries (accessed October 2021)

 

Click here to sign up to receive updates from Napp regarding our products

WHAT DOES THIS PROGRAMME OFFER?

1

2

3

Agenda

Management of adults with type 2 diabetes and chronic kidney disease: What do recent guideline updates say about the role of SGLT2 inhibitors?

10 mins

Introduction and welcome

15 mins

Recent guideline updates for the management of chronic kidney disease in people with type 2 diabetes: Key points

15 mins

What impact will the guideline updates have in clinical practice?

20 mins

Live Q&A

Speakers

Prof James Burton

Professor of Renal Medicine & Honorary Consultant Nephrologist, Leicester

Dr Sarah Davies

GP with a Special Interest in Diabetes & Education, Cardiff

Prof Partha Kar

National Specialty Advisor, Diabetes, NHS England

Management of adults with type 2 diabetes and chronic kidney disease: What do recent guideline updates say about the role of SGLT2 inhibitors?

This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed Communications has provided editorial, marketing and logistical support.

Click here to view Great Britain and Northern Ireland prescribing information

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard . Adverse events should also be reported to Janssen-Cilag Ltd on 01494567447 or at dsafety@its.jnj.com.

For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.